Acrux

Acrux Net Change in Cash

The Net Change in Cash of Acrux (ACR.AX) as of Oct 10, 2026 is 842,000.00 AUD. In the previous year, Net Change in Cash was -2.08 M AUD — a change of -140.44% (higher).

Net Change in Cash

842,000.00AUD

YoY

-140.44%

Last updated:

Net Change in Cash of Acrux is 2026 842,000.00 AUD. Net Change in Cash of Acrux was 2025 -2.08 M AUD. It decreases by -140.44% higher compared to the previous year.

The Acrux Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2019
-10.32 M AUD
Jan 1, 2020
-8.95 M AUD
Jan 1, 2021
6.06 M AUD
Jan 1, 2022
-9.44 M AUD
Jan 1, 2023
401,000.00 AUD
Jan 1, 2024
-3.29 M AUD
Jan 1, 2025
-2.08 M AUD
Jan 1, 2026
842,000.00 AUD
The Acrux Net Change in Cash history
YEARNet Change in CashYoY
842,000.00AUD-140.44%
-2.08 MAUD-36.66%
-3.29 MAUD-919.70%
401,000.00AUD-104.25%
-9.44 MAUD-255.66%
6.06 MAUD-167.78%
-8.95 MAUD-13.30%
-10.32 MAUD+87.46%
-5.50 MAUD-219.29%
4.61 MAUD-26.67%
6.29 MAUD-332.43%
-2.71 MAUD-192.23%
2.94 MAUD—
Access this data via the Eulerpool API

Acrux Stock analysis

What does Acrux do? Acrux Ltd is an Australian pharmaceutical company specializing in the development and marketing of products in the dermatology field. The company was founded in 1998 and is headquartered in Melbourne. Its history begins with the development of a groundbreaking technology called the "Sprayform® Technology," which allows the administration of liquid medications in spray form, providing numerous advantages compared to traditional administration methods. Acrux obtained the first patent for this technology in 1999 and worked on bringing it to the market. Its business model focuses on licensing its Sprayform® Technology to third parties to advance the development and marketing of products in various therapeutic areas. The company has an experienced research and development team that collaborates closely with partners to develop tailored solutions and support the entire development process, ensuring that all products meet the highest quality standards and regulatory requirements. Acrux Ltd is divided into various divisions, including products for women, diabetes, pain and inflammation, as well as neurology and psychiatry. With its Sprayform® Technology, the company has developed unique therapeutic solutions that meet patients' needs. For example, a testosterone preparation for women has been developed that is simply applied as a spray and offers higher efficacy than traditional tablets. Another product is a fast-acting pain reliever that is administered through a nasal spray. Acrux Ltd also has partnerships with major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, Pfizer, and Sanofi. These partnerships enable Acrux to market its technology globally and offer its customers a comprehensive portfolio of tailored solutions. The partner is granted exclusive rights to use the technology for specific products and markets, facilitating the development of new products and the expansion into new regions. Overall, Acrux Ltd has achieved a leadership position in the field of transdermal systems and transmucosal technologies through its innovative Sprayform® Technology. The company aims to further expand its leadership position by focusing on the development of new products and collaboration with partners. Acrux remains in constant exchange with the scientific community to incorporate the latest research and development insights into its products. Acrux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrux stock

Net Change in Cash of Acrux is 842,000.00 AUD in 2026.

Net Change in Cash of Acrux changed from -2.08 M AUD to 842,000.00 AUD, representing a -140.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Acrux since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Acrux historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Acrux

All Key Metrics — Acrux